Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. Journal of the National Cancer Institute Lin, S. H., George, T. J., Ben-Josef, E., Bradley, J., Choe, K. S., Edelman, M. J., Guha, C., Krishnan, S., Lawrence, T. S., Le, Q., Lu, B., Mehta, M., Peereboom, D., Sarkaria, J., Seong, J., Wang, D., Welliver, M. X., Coleman, C. N., Vikram, B., Yoo, S., Chung, C. H. 2013; 105 (10): 686-693

Abstract

The first annual workshop for preclinical and clinical development of radiosensitizers took place at the National Cancer Institute on August 8-9, 2012. Radiotherapy is one of the most commonly applied and effective oncologic treatments for solid tumors. It is well recognized that improved clinical efficacy of radiotherapy would make a substantive impact in clinical practice and patient outcomes. Advances in genomic technologies and high-throughput drug discovery platforms have brought a revolution in cancer treatment by providing molecularly targeted agents for various cancers. Development of predictive biomarkers directed toward specific subsets of cancers has ushered in a new era of personalized therapeutics. The field of radiation oncology stands to gain substantial benefit from these advances given the concerted effort to integrate this progress into radiation therapy. This workshop brought together expert clinicians and scientists working in various disease sites to identify the exciting opportunities and expected challenges in the development of molecularly targeted agents in combination with radiation therapy.

View details for DOI 10.1093/jnci/djt055

View details for PubMedID 23503600